Remiges Ventures
2024.09.10LUCA Science, a portfolio company of Remiges Ventures, has published significant research findings in Nature Metabolism: The study highlights how mitochondria transfer-based therapies can reduce morbidity and mortality in Leigh syndrome
2024.05.10ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced clinical collaboration between Coherus and the Cancer Research Institutes using ENB-003 for the treatment of ovarian cancer
2024.04.30InFlectis BioScience, a portfolio company of Remiges Ventures in France, was awarded a grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in multiple sclerosis. The research will be performed by Prof. Brian Popko of Northwestern University
2024.03.04Glycomine, one of Remiges Ventures’ portfolio companies, announced encouraging efficacy data from ongoing Phase2 clinical study in PMM2-CDG
2024.01.31InFlectis BioScience, a portfolio company of Remiges Ventures in France, completed enrollment of patients for the Phase 2 trial of IFB-088 for the treatment of bulbar onset Amyotrophic Lateral Sclerosis, with initial results anticipated later this year
